Obstetrics and Gynecology International

Obstetrics and Gynecology International / 2011 / Article

Clinical Study | Open Access

Volume 2011 |Article ID 548327 | https://doi.org/10.1155/2011/548327

Milagros Cruz, Ana M. Fernández-Alonso, Isabel Rodríguez, Loreto Garrigosa, Africa Caño, Pilar Carretero, Amelia Vizcaíno, Amanda Rocío Gonzalez-Ramirez, "Postcesarean Thromboprophylaxis with Two Different Regimens of Bemiparin", Obstetrics and Gynecology International, vol. 2011, Article ID 548327, 6 pages, 2011. https://doi.org/10.1155/2011/548327

Postcesarean Thromboprophylaxis with Two Different Regimens of Bemiparin

Academic Editor: Enrique Hernandez
Received30 Jul 2011
Revised18 Oct 2011
Accepted18 Oct 2011
Published26 Dec 2011


Objectives. To compare the effectiveness of postcesarean thromboprophylaxis with two different regimens of bemiparin. Material and Methods. The study included 646 women with cesarean delivery in our hospital within a 1-year period, randomly assigned to one of two groups for prophylaxis with 3500 IU bemiparin once daily for 5 days or 3500 IU bemiparin once daily for 10 days. Results. There was one case of pulmonary embolism (first day following cesarean). An additional risk factor was present in 98.52% of the women, most frequently emergency cesarean, anemia, or obesity. The only risk factors for thromboembolic disease significantly related to pulmonary thromboembolism were placental abruption and prematurity. There were no differences in thromboembolic events among the two thromboprophylaxis regimens. Conclusions. Cesarean-related thromboembolic events were reduced in our study population due to the thromboprophylactic measures taken. Thromboprophylaxis with 3500 IU bemiparin once daily for 5 days following cesarean was sufficient to avoid thromboembolic events.

1. Introduction

Venous thromboembolism (VTE) remains one of the main direct causes of maternal mortality in developed countries [14], largely due to pulmonary thromboembolism (PE) [57] which is responsible for around 20% of maternal deaths [8]. Epidemiologic studies estimate the annual frequency of deep venous thrombosis (DVT) in the general population to be from 0.16‰ [7] to 1‰ [9], of which 2% are pregnancy related [5]. There is an increased risk of thromboembolic event, either DVT or PE, during pregnancy and puerperium [5, 10], and it has been estimated that the risk of VTE is 10-fold higher [1115], reaching up to 2‰ [16].

Puerperium is the period with highest VTE risk [1214, 17, 18] which was reported to be up to 25-fold higher than that in nonpregnant women [1214]. It has been reported that 43–60% of pregnancy-related PE episodes take place during puerperium [11, 13].

The incidence of pregnancy-related VTE is estimated at 0.76 to 1.72‰ [11, 18].

The incidence is likely to be underestimated, since women are often asymptomatic [19] or present nonspecific signs or symptoms [20], and VTE during puerperium is often diagnosed or treated in a different hospital from where the delivery took place [20, 21].

The incidence of puerperium-related VTE is 0.65‰ [11].

Established risk factors for VTE during pregnancy include [9, 22] maternal age (1/800 for age >35 years; 1/1600 for age <35 years) [12, 13, 18, 23], obesity (body mass index (BMI) >30) [24, 25], preeclampsia/hypertension, parity ≥3 [16], previous VTE or congenital or acquired thrombophilia [17, 19, 20, 23, 26], smoking, diabetes [4], multiple gestation [25], black race [27], and anaemia. During the labour there are other factors [9]: type of delivery (with 3–6-fold higher risk for cesarean versus vaginal delivery, higher for emergency cesarean [13, 28, 29], and mid-cavity instrumental delivery) [28, 29], prolonged labour >12 hours [10, 25, 28], immobility; major abdominal surgery for >30 minutes during pregnancy or puerperium [12], preterm delivery [11], excessive blood loss (>1 litre), or blood transfusion. In the postpartum period, other factors may be added as dehydration, immobility, and anaemia [9, 22].

The factors that contribute the most to the incidence of thromboembolic events, due to their high prevalence, are age >35 years, obesity, and cesarean delivery [28].

Cesarean delivery increases the risk of VTE because it involves pelvic surgery that may last >30 minutes, adding to the prothrombotic effects of delivery, pregnancy weight gain, and other risk factors (see above).

The VTE incidence rate following caesarean section is 1.78‰ [11], with an odds ratio of 2 [11].

The latest guidelines [9, 16, 22] recommend that thromboprophylaxis with low-molecular-weight heparin (LMWH) in women who undergo an emergency cesarean and in women who undergo an elective cesarean also has an additional risk factor.

However, the duration of postcesarean thromboprophylaxis has been discussed and is an important factor, given the elevated risk of VTE during puerperium, especially during the first week postpartum [9, 22] and the trend to earlier postcesarean hospital discharge. So the latest guidelines [9] recommend thromboprophylaxis in these women during seven days.

However, there is no scientific evidence about the duration of the thromboprophylaxis, only clinical recommendations [7, 9, 22].

We investigated the incidence of VTE in women after cesarean section (who had not required LMWH during pregnancy) who received two different LMWH regimens in order to determine the best one to prevent this disease.

In our hospital, pneumatic compression is not used as a method of thromboprophylaxis. After using different LMWH (enoxaparin, nadroparina, …) as pharmacological thromboprophylaxis, the hospital finally established a policy with bemiparin as postoperative thromboprophylaxis (gastrointestinal, thoracic, gynaecological, obstetrics, urological, orthopedic surgery, …) several years ago.

The safety and efficacy of the LMWH bemiparin have been demonstrated for the treatment and prophylaxis of venous thromboembolism. Bemiparin is a second-generation LMWH. It is a sodium salt obtained by depolymerization of nonfractioned heparin derived from pig intestinal mucosa. Bemiparin has the lowest molecular weight (3600 Da), the longest half-life (5.3 h), and the highest anti-FXa/anti-FIIa activity ratio (8 : 1) of any second-generation LMWH [30].

The main objective was to compare the effectiveness of postcesarean thromboprophylaxis with two different regimens of bemiparin: 3500 IU once daily during five days versus ten days.

2. Material and Methods

This research was approved by the Research Ethical Committee of our university hospital.

2.1. Study

Comparison between five-day and ten-day bemiparin regimens (3500 IU once daily) as postcesarean thromboprophylaxis.

Inclusion criteria for this study were women with a cesarean delivery who had not required prophylaxis or treatment with any type of LMWH during pregnancy (low risk of VTE during pregnancy) and absence of allergy to heparin or derivatives. Later, those women who did not fulfill the duration of proposed prevention were excluded.

Outcome variables were the number of DVT and PE episodes and VTE-related maternal death up to 3 months following cesarean. Variables assessed as possible risk factors for a thromboembolic event were age, smoking, obesity (BMI > 30), hypertension, parity, multiple pregnancy, diabetes, week of delivery, type of cesarean (emergency or elective), type of anesthesia, blood loss, and immobility (at least three days).

During the period of study, in our hospital 2924 deliveries were attended; 742 cesarean were realized. All VTE cases were registered.

96 women who underwent a cesarean section were excluded because they did not fulfill the inclusion criteria.

The study included 646 women with cesarean delivery in our hospital during a 1-year period, assigned in a randomly systematic way to one of two groups for prophylaxis with 3500 IU bemiparin once daily for 5 days or 3500 IU bemiparin once daily for 10 days.

Bemiparin was administered at least 8 hours following cesarean. In case of locoregional anesthesia, Bemiparin was not given until 8 hours after removing the epidural catheter.

A complete blood count test was done to all women who underwent a cesarean within the next 24–36 hours.

We have chosen 5 and 10 days of thromboprophylaxis, because 5 days is recommended by the clinical practice guidelines before 2008, and we have chosen the comparison with 10 days, because the different clotting factors begin to normalize after the first week postpartum, although the risk may persist until the sixth week postpartum.

2.2. Statistical Analysis

Descriptive statistics were calculated for all study variables. The chi-square test was used to compare between 5-day and 10-day bemiparin.

A logistic regression model was used to analyze the demographic and morphometric variables and likelihood of DVT/PE (dependent variables) with each regimen.

3. Results and Discussion

3.1. Results

During this period of time, 646 women with cesarean delivery met the study inclusion criteria. Table 1 shows the characteristics of the women and their possible thromboembolic risk factors during their pregnancy.

ThromboprophylacticGroup AGroup B
regimenBemiparin 3500 IU/5 daysBemiparin 3500 IU/10 days

Number of cases ( )311335
Mean age ± SD31.37 ± 5.2431.06 ± 5.62
Age ≥35 years (%)89 (28.61%)98 (29.25%)
Parity ( ) (%)
 0149 (47.9%)174 (51.9%)
 190 (28.9%)101 (30.1%)
 246 (14.8%)41 (12.2%)
 313 (4.2%)13 (3.9%)
 ≥413 (4.2%) 6 (1.8%)
BMI ( ) (%)
 BMI > 30142 (45.8%)116 (34.62%)
 BMI > 3536 (11.6%)22 (6.56%)
Smoking ( ) (%)51 (16.5%)40 (11.9%)
 >10 cigs./day16 (16%)9 (2.25%)
Drug consumption ( ) (%)1 (0.3%)1 (0.3%)
Multiple pregnancy ( ) (%)13 (4.2%)19 (5.6%)
Hypertension ( ) (%)
 Chronic hypertension6 (1.9%)0
 PIH in previous pregnancy4 (1.3%)6 (1.8%)
 PIH in current pregnancy 34 (10.9%) 35 (10.4%)
Diabetes ( ) (%)15 (4.82%)26 (1.8%)
 Type I3 (1%)2 (0.6%)
 Gestational diabetes8 (2.6%)18 (5.4%)
 Carbohydrate intolerance4 (1.3%)6 (1.8%)
Previous heart disease (%)01 (0.3%)
Immobility ( ) (%)01 (0.3%)

BMI: body mass index, PIH: pregnancy-induced hypertension.

Mean age was years, 59.7% were nulliparous, 9% had ≥2 previous deliveries, and 14% were smokers. BMI indicated that 42.3% of patients in the bemiparin groups were obese (BMI > 30). Other possible risk factors for VTE were diabetes (0.8–4.82%), hypertension during pregnancy (10.7%), and multiple pregnancy (5%). There was a negligible incidence of prolonged immobility, drug consumption, or heart disease in our study population.

Table 2 shows the characteristics of the deliveries and the associated thromboembolism risk factors. Cesareans were almost always at term, with only 12.7% preterm, while 73.6% were emergency cesareans, an added thrombosis risk factor. The most frequent anesthesia was locoregional (88.3%). Other potential thrombosis factors (due to the possible underlying disease) were placental abruption (2.2%) and intrauterine growth retardation (IUGR) (8.5%). In the present study, only placental abruption and gestational age (preterm) were significantly related to PE ( ).

ThromboprophylacticGroup AGroup B
regimenBemiparin 3500 IU/5 daysBemiparin 3500 IU/10 days
(number of cases) ( ) ( )

Type of cesarean ( ) (%)
 Elective82 (26.4%)88 (26.4%)
 Emergency 229 (73.6%) 247 (73.6%)
Type of anesthesia ( ) (%)
 Locoregional278 (89.7%)290 (86.6%)
 General 31 (10.3%) 45 (13.77%)
Delivery GW (mean ± SD)
Preterm ( ) (%)40 (12.9%)41 (12.4%)
Placental abruption ( ) (%)7 (2.3%)7 (2.1%)
IUGR ( ) (%)24 (7.7%)31 (9.3%)

IUGR: intrauterine growth retardation, GW: weeks of gestation.

Table 3 depicts the thrombosis risk factors recorded after the cesarean. Anemia ( ) was the most prevalent risk factor (75.4% women after cesarean section), followed by hypertension (4.9%) and infection (6.4%). Almost all women (98.53%) had an additional risk factor beside the cesarean.

Thromboprophylactic regimenGroup AGroup B
(number of cases)Bemiparin 3500 IU/5 daysBemiparin 3500 IU/10 days
( ) ( )

Postcesarean anemia ( ) (%)
222 (71.38%)249 (74.32%)
161 (51.8%)179 (53.5%)
72 (23.4%) 89 (26.6%)
Infection21 (6.8%)20 (6%)
Seroma17 (5.5%)16 (4.8%)
Postcesarean hypertension15 (5.7%)9 (4%)

Hb: hemoglobin.

There were neither maternal deaths nor any DVT cases.

There was only one PE case. This case was in a 25-year-old nulliparous woman assigned to group B with a BMI of 29.5 and no family history of thrombosis; her smoking habit of <10 cigarettes/day was the only risk factor during pregnancy. She was hospitalized in week 32 with placental abruption symptoms and underwent emergency cesarean with locoregional anesthesia. At this time two other risk factors were added up: emergency cesarean section and vaginal bleeding. The fetus was delivered alive with appropriate weight for gestational age. The mother presented with moderate anemia that required intravenous iron treatment. On the first postoperative day, before beginning the thrombophylaxis with bemiparin, she reported difficulty in breathing and pain in right costodiaphragmatic recess. PE was diagnosed after clinical examination, elevated D-dimer, and complementary tests: perfusion lung scintigraphy (PE in lateral and medial segments of medial lobe of right lung) and bilateral lower limb Doppler’s ultrasound examination (normal). Consequently, a therapeutic LMWH regimen was started instead of the thromboprophylaxis regimen and was subsequently replaced with oral anticoagulant therapy. A hypercoagulation test at 6 months ruled out thrombophilias.

Hence, the incidence of VTE in this series (women with cesarean delivery) was 1,54% and the incidence of VTE in total number of deliveries was 0,34% (1/2924).

Considering that the only PE case occurred on the first postoperative day, before beginning the thromboprophylaxis, comparisons among the different LMWH regimens were not appropriate.

3.2. Discussion

There is a continual and exhaustive surveillance of VTE risk factors during pregnancy and puerperium at our hospital, and appropriate thromboprophylactic measures are implemented when they are detected [31].

Those measures are recommendations of exercises for early mobilization for foot and legs, early ambulation (within two hours after the vaginal delivery and 6–8 hours after cesarean section), women are well hydrated with serum therapy in puerperium, and liquid and food are administered early (immediately after vaginal delivery; at 4–6 hours after cesarean section with locoregional anesthesia and 6–8 hours after cesarean section with general anesthesia) and LMWH thromboprophylaxis starts at least 8 hours following cesarean.

This policy may explain why only one episode of VTE was observed in the hospital during the period studied; this case took place during the first 24 hours after cesarean for placental abruption.

Given the total number of deliveries at the hospital (2924) during this period, an incidence from 2 to 5 VTE cases related to pregnancy, delivery, and puerperium could be expected [10, 11, 28].

The fact that only one case was observed may suggest a lower presence of risk factors in our population; nevertheless, 98.53% of studied women had at least one other thrombosis risk factor besides the cesarean surgery.

When we analyzed the risk factors, compared with that reported in other studies, we observed that, although women in our study have risk factors for VTE (age over 35 years 30%, obesity 30%, emergency cesarean section >70%, anaemia 50%). We only had one case of VTE (risk factors presented: smoking, emergency cesarean section, preterm delivery, vaginal bleeding, and severe anemia).

The most frequent risk factors in our population were emergency cesarean, anaemia, and obesity. Special attention is given to VTE prevention at our center, and all women are closely followed up for risk factors throughout their pregnancy and puerperium to determine any need for thromboprophylaxis.

In our hospital, the thromboprophylaxis measures may help to explain our finding of a lower-incidence VTE (0,34%) than that of in published reports [11, 32]. Regional anesthesia (epidural/dural) was used in more than 90%, cases of caesarean section, and this fact can reduce the risk of VTE [24].

Historically in our hospital, LMWH was prescribed in all cases of cesarean delivery; since the early postcesarean hospital discharge policy (third day following cesarean) began, we reconsidered whether to continue the prophylaxis after the hospital discharge or not.

Some authors have recommended the postcesarean use of LMWH only when there is an additional risk factor or in cases of emergency cesarean [29]. However, we agree with the recommendations of several clinical practice guidelines [9, 22], which have recommended that the threshold for prescribing thromboprophylaxis should be lower in the postnatal period than that in the antenatal period since the risk of developing VTE per day is higher and the duration of exposure shorter. Even some of them [9] recommend that all women, who have had an emergency caesarean section or an elective cesarean section and have one or more additional risk factors for VTE, should receive thromboprophylaxis with LMWH for seven days.

We prescribe LMWH in all cesareans, both elective and emergency, because we cannot know a priori whether another thrombosis risk factor will appear in puerperium (e.g., anaemia, infection, hypertension) or whether a longer rest period will be required (e.g., for postpuncture headache, infection). In fact, 98.53% of the present series of women with cesarean had at least one more risk factor.

At our hospital, the high rate of VTE risk factors may be due to the continual and exhaustive surveillance of these VTE risk factors, included period puerperium; so you might be able to detect more risk factors than other hospitals. In our department, a blood test is performed within 24–36 hours after a cesarean section to count red blood cells, leukocytes, and platelets, which detects anaemia that otherwise may go unnoticed.

In our view, the benefits of postcesarean LMWH administration in minimizing the risk of thromboembolic events greatly outweigh the low level of risk associated with its use [33, 34].

In our study, we have not had any adverse effects from the administration of LMWH (bleeding, thrombocytopenia induced by LMWH).

We agree with the recommendations of recent clinical practice guidelines [16]; and although, a cost-effectiveness analysis was not completed specifically for this population subgroup, the cost-effectiveness model for medical patients indicates that prophylaxis with LMWH is cost effective for patients at increased risk. In our investigation, bemiparin 3500 once daily during five days has been sufficient to prevent thromboembolic events, so health costs are lower (two days less than recommended in the clinical practice guideline) [9], although clotting factors may take a few more days to normalize.

4. Conclusions

A reduction in the incidence of thromboembolic disease can be achieved by surveillance of risk factors during the pregnancy, delivery, and puerperium alongside physical measures and thromboprophylaxis with low-molecular-weight heparin.

In case of women with cesarean delivery, we recommend adding thromboprophylaxis with low-molecular-weight heparin (like Bemiparin) during five days following cesarean.

These actions seem to be adequate to avoid thromboembolic events, although the continuation of thromboprophylaxis should be considered if other risk factors emerge.


The authors thank all members of the Department of Obstetrics and Gynecology of the San Cecilio University Hospital in Granada, without whose collaboration this study would have not been possible. All authors state that this study was supported by a research grant from the Laboratorios Fcos. ROVI, SA, and confirm that the results of this manuscript have not been distorted by it. This study was made under routine clinical conditions and was approved by the Research Ethical Committee of our university hospital.


  1. J. Drife, “Thromboembolism,” British Medical Bulletin, vol. 67, pp. 177–190, 2003. View at: Publisher Site | Google Scholar
  2. P. A. Clyburn, “Editorial 2. Early thoughts on ‘why mothers die 2000–2002’,” Anaesthesia, vol. 59, no. 12, pp. 1157–1159, 2004. View at: Publisher Site | Google Scholar
  3. R. L. Andres and A. Miles, “Venous thromboembolism and pregnancy,” Obstetrics and Gynecology Clinics of North America, vol. 28, no. 3, pp. 613–630, 2001. View at: Publisher Site | Google Scholar
  4. A. H. James, V. F. Tapson, and S. Z. Goldhaber, “Thrombosis during pregnancy and the postpartum period,” American Journal of Obstetrics and Gynecology, vol. 193, no. 1, pp. 216–219, 2005. View at: Publisher Site | Google Scholar
  5. J. A. Heit, C. E. Kobbervig, A. H. James, T. M. Petterson, K. R. Bailey, and L. J. Melton, “Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study,” Annals of Internal Medicine, vol. 143, no. 10, pp. 697–706, 2005. View at: Google Scholar
  6. M. De Swiet, “Maternal mortality: confidential enquiries into maternal deaths in the United Kingdom,” American Journal of Obstetrics and Gynecology, vol. 182, no. 4, pp. 760–766, 2000. View at: Google Scholar
  7. S. Gates, P. Brocklehurst, and L. J. Davis, “Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period,” Cochrane Database of Systematic Reviews, no. 2, p. CD001689, 2002. View at: Google Scholar
  8. J. Chang, L. D. Elam-Evans, C. J. Berg et al., “Pregnancy-related mortality surveillance—United States, 1991–1999,” MMWR Surveillance Summaries, vol. 52, no. 2, pp. 1–8, 2003. View at: Google Scholar
  9. Scottish Intercollegiate Guidelines Netword (SIGN), Prevention and Management of Venous Thromboembolism, A National Clinical Guideline, 2010.
  10. O. P. Phillips, “Venous thromboembolism in the pregnant woman,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 48, no. 11, supplement, pp. 921–929, 2003. View at: Google Scholar
  11. E. L. Simpson, R. A. Lawrenson, A. L. Nightingale, and R. D. T. Farmer, “Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database,” British Journal of Obstetrics and Gynaecology, vol. 108, no. 1, pp. 56–60, 2001. View at: Publisher Site | Google Scholar
  12. F. A. Anderson Jr. and F. A. Spencer, “Risk factors for venous thromboembolism,” Circulation, vol. 107, no. 23, supplement 1, pp. I9–I16, 2003. View at: Publisher Site | Google Scholar
  13. Scottish Intercollegiate Guidelines Network (SIGN), Prophylaxis of Venous Thromboembolism, Guideline, 2002.
  14. A. Romero, “Risk of venous thromboembolic disease in women. A qualitativ systematic review,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 121, no. 1, pp. 8–17, 2005. View at: Google Scholar
  15. S. M. Bates, I. A. Greer, I. Pabinger, S. Sofaer, and J. Hirsh, “Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, supplement, 2008. View at: Publisher Site | Google Scholar
  16. Royal Collegue of Physicians, National Clinical Guideline Centre-Acute and Chronic Conditions. Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital, 2010.
  17. A. Gerhardt, R. E. Scharf, M. W. Beckmann et al., “Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium,” The New England Journal of Medicine, vol. 342, no. 6, pp. 374–380, 2000. View at: Publisher Site | Google Scholar
  18. J. Conard, M. H. Horellou, and M. M. Samama, “Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians,” Journal des Maladies Vasculaires, vol. 34, no. 5, pp. 300–313, 2009. View at: Google Scholar
  19. A. C. Spyropoulos, “Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients,” Chest, vol. 128, no. 2, pp. 958–969, 2005. View at: Publisher Site | Google Scholar
  20. A. J. Duhl, M. J. Paidas, S. H. Ural et al., “Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes,” American Journal of Obstetrics and Gynecology, vol. 197, no. 5, pp. 457.e1–457.e21, 2007. View at: Publisher Site | Google Scholar
  21. M. Cruz, A. Caño, E. Hidalgo et al., “Maternal mortality in San Cecilio University Hospital during 1988–2000,” Clinical Investigation, vol. 4, no. 4, pp. 324–329, 2001. View at: Google Scholar
  22. Royal College of Obstetricians and Gynaecologists, Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium, Green-Top Guidelines, 2009.
  23. Royal College of Obstetrics and Gynaecologists, Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management, Green-Top Guidelines, 2007.
  24. A. H. James, M. G. Jamison, L. R. Brancazio, and E. R. Myers, “Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors, and mortality,” American Journal of Obstetrics and Gynecology, vol. 194, no. 5, pp. 1311–1315, 2006. View at: Publisher Site | Google Scholar
  25. D. R. Danilenko-Dixon, J. A. Heit, M. D. Silverstein et al., “Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study,” American Journal of Obstetrics and Gynecology, vol. 184, no. 2, pp. 104–110, 2001. View at: Publisher Site | Google Scholar
  26. I. Martinelli, C. Legnani, P. Bucciarelli, E. Grandone, V. De Stefano, and P. M. Mannucci, “Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia,” Thrombosis and Haemostasis, vol. 86, no. 3, pp. 800–803, 2001. View at: Google Scholar
  27. A. Seddighzadeh, U. Zurawska, R. Shetty, and S. Z. Goldhaber, “Venous thromboembolism in patients undergoing surgery: low rates of prophylaxis and high rates of filter insertion,” Thrombosis and Haemostasis, vol. 98, no. 6, pp. 1220–1225, 2007. View at: Publisher Site | Google Scholar
  28. P. E. Marik and L. A. Plante, “Venous thromboembolic disease and pregnancy,” The New England Journal of Medicine, vol. 359, no. 19, pp. 2025–2033, 2008. View at: Publisher Site | Google Scholar
  29. M. Bazzan and V. Donvito, “Low-molecular-weight heparin during pregnancy,” Thrombosis Research, vol. 101, no. 1, pp. V175–V186, 2001. View at: Google Scholar
  30. J. Martinez-Gonzalez, L. Vila, and C. Rodriguez, “Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism,” Expert Review of Cardiovascular Therapy, vol. 6, pp. 793–802, 2008. View at: Google Scholar
  31. A. M. Fernández, M. Cruz, P. Carretero, I. Rodríguez, L. Garrigosa, and A. Vizcaíno, “Obstetric thromboprophylaxis eficacy,” Revista de Obstetricia y Ginecología de Venezuela, vol. 68, no. 4, pp. 215–221, 2008. View at: Google Scholar
  32. A. Blanco-Molina, J. Trujillo-Santos, J. Criado et al., “Venous thromboembolism during pregnancy or postpartum: findings form the RIETE Registry,” Thrombosis and Haemostasis, vol. 97, no. 2, pp. 186–190, 2007. View at: Publisher Site | Google Scholar
  33. B. S. Andersen, F. H. Steffensen, H. T. Sorensen, G. L. Nielsen, and J. Olsen, “The cumulative incidence of venous thromboembolism during pregnancy and puerperium—an 11 year Danish population-based study of 63,300 pregnancies,” Acta Obstetricia et Gynecologica Scandinavica, vol. 77, no. 2, pp. 170–173, 1998. View at: Google Scholar
  34. M. Blondon, A. Perrier, M. Nendaz et al., “Thromboprophylaxis with low-molecular-weight heparin after cesarean delivery: a decision analysis,” Thrombosis and Haemostasis, vol. 103, no. 1, pp. 129–137, 2010. View at: Publisher Site | Google Scholar

Copyright © 2011 Milagros Cruz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles